PMID- 19604317
OWN - NLM
STAT- MEDLINE
DCOM- 20100719
LR  - 20221005
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 13
IP  - 8B
DP  - 2009 Aug
TI  - A HCMV pp65 polypeptide promotes the expansion of CD4+ and CD8+ T cells across a 
      wide range of HLA specificities.
PG  - 2131-2147
LID - 10.1111/j.1582-4934.2008.00531.x [doi]
AB  - Human cytomegalovirus (HCMV) can cause life-threatening disease in infected 
      hosts. Immunization with human leukocyte antigen (HLA)-restricted immunodominant 
      synthetic peptides and adoptive transfer of epitope-specific T cells have been 
      envisaged to generate or boost HCMV-specific cellular immunity, thereby 
      preventing HCMV infection or reactivation. However, induction or expansion of T 
      cells effective against HCMV are limited by the need of utilizing peptides with 
      defined HLA restrictions. We took advantage of a combination of seven predictive 
      algorithms to identify immunogenic peptides of potential use in the prevention or 
      treatment of HCMV infection or reactivation. Here we describe a pp65-derived 
      peptide (pp65(340-355), RQYDPVAALFFFDIDL: RQY16-mer), characterized by peculiar 
      features. First, RQY-16mer is able to stimulate HCMV pp65 specific responses in 
      both CD4(+) and CD8(+) T cells, restricted by a wide range of HLA class I and II 
      determinants. Second, RQY-16mer is able to induce an unusually wide range of 
      effector functions in CD4(+) T cells, including proliferation, killing of 
      autologous HCMV-infected target cells and cytokine production. Third, and most 
      importantly, the RQY-16mer is able to stimulate CD4(+) and CD8(+) T-cell 
      responses in pharmacologically immunosuppressed patients. These data suggest that 
      a single reagent might qualify as synthetic immunogen for potentially large 
      populations exposed to HCMV infection or reactivation.
FAU - Provenzano, Maurizio
AU  - Provenzano M
AD  - Institute of Surgical Research and Hospital Management, and Department of 
      Biomedicine, University Hospital Basel, Switzerland.
FAU - Sais, Giovanni
AU  - Sais G
AD  - Institute of Surgical Research and Hospital Management, and Department of 
      Biomedicine, University Hospital Basel, Switzerland.
FAU - Bracci, Laura
AU  - Bracci L
AD  - Institute of Surgical Research and Hospital Management, and Department of 
      Biomedicine, University Hospital Basel, Switzerland.
FAU - Egli, Adrian
AU  - Egli A
AD  - Transplantation Virology, Institute for Medical Microbiology, University of 
      Basel, Switzerland.
FAU - Anselmi, Maurizio
AU  - Anselmi M
AD  - Institute of Surgical Research and Hospital Management, and Department of 
      Biomedicine, University Hospital Basel, Switzerland.
FAU - Viehl, Carsten T
AU  - Viehl CT
AD  - Institute of Surgical Research and Hospital Management, and Department of 
      Biomedicine, University Hospital Basel, Switzerland.
FAU - Schaub, Stefan
AU  - Schaub S
AD  - Department of Transplantation Immunology and Nephrology, University Hospital 
      Basel, Switzerland.
FAU - Hirsch, Hans H
AU  - Hirsch HH
AD  - Transplantation Virology, Institute for Medical Microbiology, University of 
      Basel, Switzerland.
FAU - Stroncek, David F
AU  - Stroncek DF
AD  - Department of Transfusion Medicine, Infectious Diseases and Immunogenetic 
      Section, Clinical Center, NIH, Bethesda, MD, USA.
FAU - Marincola, Francesco M
AU  - Marincola FM
AD  - Department of Transfusion Medicine, Infectious Diseases and Immunogenetic 
      Section, Clinical Center, NIH, Bethesda, MD, USA.
FAU - Spagnoli, Giulio C
AU  - Spagnoli GC
AD  - Institute of Surgical Research and Hospital Management, and Department of 
      Biomedicine, University Hospital Basel, Switzerland.
LA  - eng
GR  - ZIA CL002118-03/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (DNA Primers)
RN  - 0 (HLA Antigens)
RN  - 0 (Phosphoproteins)
RN  - 0 (Viral Matrix Proteins)
RN  - 0 (cytomegalovirus matrix protein 65kDa)
SB  - IM
MH  - Algorithms
MH  - Amino Acid Sequence
MH  - Base Sequence
MH  - CD4-Positive T-Lymphocytes/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - DNA Primers
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Molecular Sequence Data
MH  - Phosphoproteins/chemistry/*physiology
MH  - Polymerase Chain Reaction
MH  - Viral Matrix Proteins/chemistry/*physiology
PMC - PMC3549594
MID - NIHMS421460
EDAT- 2009/07/17 09:00
MHDA- 2010/07/20 06:00
PMCR- 2009/08/01
CRDT- 2009/07/17 09:00
PHST- 2009/07/17 09:00 [entrez]
PHST- 2009/07/17 09:00 [pubmed]
PHST- 2010/07/20 06:00 [medline]
PHST- 2009/08/01 00:00 [pmc-release]
AID - JCMM531 [pii]
AID - 10.1111/j.1582-4934.2008.00531.x [doi]
PST - ppublish
SO  - J Cell Mol Med. 2009 Aug;13(8B):2131-2147. doi: 10.1111/j.1582-4934.2008.00531.x.